go to home page team portfolio news contact

 

We're a venture capital firm specializing in life sciences. Since our launch in 2001, we’ve supported more than 25 young companies. We invest in traditional healthcare opportunities as well as emerging areas — such as nutrition, wellness, and green technology — in which we’ve built one of the largest portfolios in the country.

Our firm was created by people with both investment know-how and direct experience in getting new ventures off the ground. We use this expertise to invest in what we know best: exceptional opportunities in their early stages. And then we take an active, ongoing role in helping entrepreneurs develop the right strategy, team, and connections to succeed.

Recent News Releases  
           
  05 08 09  > Teikoku acquires Tranvanti Pharma, a Prolog II portfolio company
03 02 09  > Veran receives Frost & Sullivan technology innovation award for its IG4 system
02 17 09  > Divergence raises $11.8M in financing to further advance its nematicide program
01 27 09  > Corazonas partners with WomenHeart to help lower cholesterol and fight heart disease
01 12 09  > Singulex closes $19M in financing to develop its immunoassay technology for the diagnostics market
11 17 08  > Prolog Ventures is among venture capital firms honored by Astia for support of women entrepreneurs
           
 

Quick Notes

 

Recent Media Coverage

 
           


The Natural Dentist
New packaging
for oral rinses and
toothpastes
pictured in
The New York Times

 
Attune
Probiotic wellness
bars win Health
Magazine’s

“Healthiest 2009”
award

 
Prolog
Michelle Murray spoke
on a VC panel at
the 8th Annual Life Science Technology Venture Forum at Rice University

 
Prolog
Brian Clevinger spoke on the “Funding and Financing in 2009 & Beyond” panel at Ag
Innovation Showcase

 

 

post masthead
 
Prolog views nutrition and wellness as a
bright spot in the venture capital landscape:
“People still read food labels”
Complete Article >
     

post masthead
 
Singulex' Erenna system used by Washington University in St. Louis to aid disease research
Complete Article >
     


  Prolog discusses the
merits of investing
in the health and
wellness space
Complete Article >
     
 

post masthead
 
Research suggests that APT Therapeutics' experimental drug helps block blood platelets from aiding cancer cells
Complete Article >
     

american venture
  Prolog offers advice
for entrepreneurs
seeking capital
Complete Article >
     


  Corazonas Foods
and LightFull Foods receive high rankings within “25 Best New Foods for You”
cover story
Article Excerpts >
   

T O P